Public Release: 

Obesity a liability in cancer immunotherapy

Rockefeller University Press

IMAGE?

IMAGE: New research suggests that the accumulation of fat in older mice, as displayed here, is responsible for their increased susceptibility to deadly inflammation in response to anti-cancer immunotherapy. view more

Credit: Mirsoian et al, 2014

Packing on the pounds may lead to dangerous inflammation in response to anti-cancer treatment, according to a study by William Murphy and colleages at UC Davis. The study, published in The Journal of Experimental Medicine, shows that overweight mice develop lethal inflammation in response to certain anti-cancer therapies, suggesting a possible link between body weight and adverse side effects in cancer patients treated with similar protocols.

Cancer treatment has been revolutionized by new approaches aimed at stimulating the body's own immune system to fight off tumor cells. These "immunotherapy" approaches have proven successful in many types of cancer, but they are also associated with dangerous inflammation in some patients. This group had previously shown that treating mice with a combination of immune-activating stimuli--anti-CD40 antibodies and interleukin (IL)-2--stimulates tumor-fighting immune cells to eradicate cancer in young mice. In old mice, however, the same treatment triggered deadly inflammation.

As with humans, mice often accumulate fat as they age. Murphy's group now finds that lethal inflammation in response to anti-CD40/IL-2 immunotherapy is determined more by fat than age. Like old mice, young, obese mice succumbed to lethal inflammation in response to treatment. And putting older mice on diets protected them. This suggests that the results of preclinical immunotherapy studies in mice and humans--primarily performed on young subjects--should be interpreted with caution, particularly as cancer is a disease that predominately affects the elderly.

###

Mirsoian, A., et al. 2014. J. Exp. Med. doi:10.1084/jem.20140116

About The Journal of Experimental Medicine

The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit http://www.jem.org .

Research reported in the press release was supported by the National Institutes of Health and the National Institute on Aging.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.